BDA-366 is primarily researched for its potential in cancer therapy, particularly in targeting and inducing apoptosis in cancer cells. It functions as a BH3 mimetic, which means it can bind to and inhibit anti-apoptotic proteins like Bcl-2, thereby promoting programmed cell death in malignant cells. This mechanism makes it a promising candidate for treating cancers that overexpress Bcl-2, such as certain types of leukemia and lymphoma. Additionally, its selective action on cancer cells while sparing normal cells highlights its potential for developing targeted therapies with reduced side effects. Ongoing studies are exploring its efficacy in combination with other treatments to enhance its anticancer effects.